Search Results - "Gueyffier, F."

Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross‐over controlled trial in a rare disease by Gaillard, S., Dupuis‐Girod, S., Boutitie, F., Rivière, S., Morinière, S., Hatron, P.‐Y., Manfredi, G., Kaminsky, P., Capitaine, A.‐L., Roy, P., Gueyffier, F., Plauchu, H.

“…Summary Background Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder associated with abnormal angiogenesis and disabling epistaxis. Tranexamic…”
Get full text

Publication bias in pharmacogenetics of statin-associated muscle symptoms: A meta-epidemiological study by Gougeon, A., Aribi, I., Guernouche, S., Lega, J.C., Wright, J.M., Verstuyft, C., Lajoinie, A., Gueyffier, F., Grenet, G.

“…Statin-associated muscle symptoms (SAMS) are a major cause of treatment discontinuation. Clinical Pharmacogenetics Implementation Consortium (CPIC) recommend…”
Get full text

Pharmacokinetic/pharmacodynamic model of a methionine starvation based anti-cancer drug by Eymard, N., Bessonov, N., Volpert, V., Kurbatova, P., Gueyffier, F., Nony, P.

“…A new therapeutic approach against cancer is developed by the firm Erytech. This approach is based on starved cancer cells of an amino acid essential to their…”
Get full text

Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials by Rehman, M.B, Tudrej, B.V, Soustre, J, Buisson, M, Archambault, P, Pouchain, D, Vaillant-Roussel, H, Gueyffier, F, Faillie, J.-L, Perault-Pochat, M.-C, Cornu, C, Boussageon, R

“…Abstract Background Guidelines for type 2 diabetes (T2D) recommend reducing HbA1c through lifestyle interventions and glucose-lowering drugs (metformin, then…”
Get full text

[OP.4A.03] PUBLIC HEALTH IMPACT OF CARDIOVASCULAR TREATMENTS IN PRIMARY PREVENTION: A SIMULATION STUDY ON A VIRTUAL REALISTIC POPULATION by Fall, M, Le, H, Marchant, I, Gueyffier, F

“…OBJECTIVE:Cardiovascular disease is responsible for about one third of cardiovascular death worldwide and is the first cause of morbidity-mortality in France…”
Get full text

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France on volume and cost of drug deliveries, assessed with administrative databases by Mari, K., Rannou, F., Guillemin, F., Elegbede, M., Gueyffier, F., Badot, G., Mistretta, F.

“…As one of the leading causes of disability in adults worldwide, its toll on patients and its economic burden for payers are substantial. The issue of change in…”
Get full text

Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis by Mainbourg, S., Cucherat, M., Provencher, S., Bertoletti, L., Nony, P., Gueyffier, F., Mismetti, P., Grange, C., Durieu, I., Kilo, R., Laporte, S., Grenet, G., Lega, J.-C.

“…The direct oral anticoagulants (DOAC) have similar half-lives, but the dosing regimen varies between once daily (QD) or twice daily (BID). For some…”
Get full text

Risk Reduction or Treat-To-Target Strategy? Economic Assessment of Statin use in Cardiovascular Prevention by Gafsi, J, Gueyffier, F, Marchant, I

“…Background The latest ACC/AHA guidelines on high blood cholesterol management have raised controversy regarding especially the elimination of the LDL-C…”
Get full text

Corrigendum to “Abstracts Presented at EACPT 2017”: Clin Ther 2017;39:e66 by Gafsi, J., Gueyffier, F., Marchant, I.

Get full text

Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes? by Bejan-Angoulvant, T, Cornu, C, Archambault, P, Tudrej, B, Audier, P, Brabant, Y, Gueyffier, F, Boussageon, R

“…Abstract Recent recommendations regarding type 2 diabetes (T2D) patients’ treatments have focused on personalizing glycosylated haemoglobin (HbA1c ) targets…”
Get full text

[OP.3B.01] VALIDATION OF FRAMINGHAM AND SCORE IN 30560 PATIENTS WITH HYPERTENSION by Le, H, Marchant, I, Subtil, F, Boissel, J, Gueyffier, F

“…OBJECTIVE:To validate the Framingham and SCORE predictors for cardiovascular death and death from coronary heart diseases in 30560 individuals with…”
Get full text

Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: What is the level of evidence? by Boussageon, R, Gueyffier, F, Cornu, C

“…Abstract Antidiabetic drugs for type 2 diabetes receive marketing authorization if they show efficacy in reducing levels of HbA1c . However, efficacy on this…”
Get full text

[OP.1A.06] DOES DIABETES REALLY HARM WOMEN MORE THAN MEN? ANALYSES FROM 30560 INDIVIDUAL PATIENT DATA by Le, H, Subtil, F, Cerou, M, Marchant, I, Lindholm, L, Thijs, L, Gueyffier, F

“…OBJECTIVE:Men are more likely than women to develop type 2 diabetes. However, women with diabetes are at higher risk of morbidity and mortality from diabetes…”
Get full text

How individual participant data meta-analyses have influenced trial design, conduct, and analysis by Tierney, Jayne F, Pignon, Jean-Pierre, Gueffyier, Francois, Clarke, Mike, Askie, Lisa, Vale, Claire L, Burdett, Sarah

“…Abstract Objectives To demonstrate how individual participant data (IPD) meta-analyses have impacted directly on the design and conduct of trials and highlight…”
Get full text

New insights on the Pioglitazone risk-benefit ratio in European Population by Arriagada, S, Gueyffier, F, Milles, R, Marchant, I

“…The number of cardiovascular events prevented was greater than the number of bladder cancers whatever the subgroup studied, with a ratio ranging from 21 in men…”
Get full text

PP084—A European score predicts better south american cardiovascular risk than framingham risk equations by Marchant, I, Gueyffier, F

Get full text

Association between difference in blood pressure reduction and risk of cardiovascular events in a type 2 diabetes population: A meta-regression analysis by Grenet, G., Le, H.H., Bejan-Angoulvant, T., Erpeldinger, S., Boussageon, R., Kassaï, B., Moulin, P., Gueyffier, F., Cucherat, M.

“…Recent US recommendations indicate a target blood pressure (BP) of 130/80mmHg for patients with type 2 diabetes (T2D). Our aim was to characterize the…”
Get full text

Multivariate meta-analysis using individual participant data by Riley, R. D., Price, M. J., Jackson, D., Wardle, M., Gueyffier, F., Wang, J., Staessen, J. A., White, I. R.

“…When combining results across related studies, a multivariate meta‐analysis allows the joint synthesis of correlated effect estimates from multiple outcomes…”
Get full text

Are we using blood pressure-lowering drugs appropriately? Perhaps now is the time for a change by Gueyffier, F, Wright, J

“…This topic seems particularly appropriate since this year is the 20th Anniversary of the Cochrane Collaboration. The Cochrane Collaboration and the…”
Get full text

[OP.1D.08] SYNERGETIC PREVENTION OF SUDDEN DEATH BY ACEI, STATIN AND GLIFLOZIN IN TYPE 2 DIABETES: A SIMULATION STUDY by Le, H, Marchant, I, Boissel, J.P, Nony, P, Kassai, B, Cornu, C, Gueyffier, F

“…OBJECTIVE:Sudden cardiac death (SCD) is at the first rank of cardiovascular death causes in patients with type 2 diabetes (T2D). ACEIs and statins, but not…”
Get full text